193 related articles for article (PubMed ID: 10234741)
1. [3H]Pramipexole: a selective radioligand for the high affinity dopamine D2 receptor in bovine striatal membranes.
Ohnmacht U; Tränkle C; Mohr K; Gmeiner P
Pharmazie; 1999 Apr; 54(4):294-7. PubMed ID: 10234741
[TBL] [Abstract][Full Text] [Related]
2. Expression of the bovine striatal D2 receptor, but not the D1 receptor, in bovine adrenal medulla.
Maroto R; López MG; del Valle M; Naranjo JR; Mellström B; García AG
Mol Pharmacol; 1995 Jan; 47(1):40-50. PubMed ID: 7838132
[TBL] [Abstract][Full Text] [Related]
3. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
4. Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat.
Hilakivi I; Rinne J; Marjamäki P
Pol J Pharmacol; 1999; 51(4):311-6. PubMed ID: 10540962
[TBL] [Abstract][Full Text] [Related]
5. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.
Piercey MF; Walker EL; Feldpausch DL; Camacho-Ochoa M
Neurosci Lett; 1996 Nov; 219(2):138-40. PubMed ID: 8971799
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and binding properties of several new dopaminergic ligands.
Tuce Z; Soskić V; Joksimović J
Drug Des Discov; 1994 Jun; 11(4):251-8. PubMed ID: 7727678
[TBL] [Abstract][Full Text] [Related]
7. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
Wong DT; Threlkeld PG; Bymaster FP
Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
[TBL] [Abstract][Full Text] [Related]
9. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
[TBL] [Abstract][Full Text] [Related]
10. Receptor-receptor link in membranes revealed by ligand competition: example for dopamine D1 and D2 receptors.
Seeman P; Sunahara RK; Niznik HB
Synapse; 1994 May; 17(1):62-4. PubMed ID: 8042146
[TBL] [Abstract][Full Text] [Related]
11. Link between dopamine D1 and D2 receptors in rat and human striatal tissues.
Seeman P; Tallerico T
Synapse; 2003 Mar; 47(4):250-4. PubMed ID: 12539197
[TBL] [Abstract][Full Text] [Related]
12. Competitive MS binding assays for dopamine D2 receptors employing spiperone as a native marker.
Niessen KV; Höfner G; Wanner KT
Chembiochem; 2005 Oct; 6(10):1769-75. PubMed ID: 16149041
[TBL] [Abstract][Full Text] [Related]
13. New substituted 2-methylthiomethyl- and 2-methylsulphinylmethylenebenzimidazoles with D2/5-HT1A activity.
Kostić-Rajacić S; Soskić V; Joksimović J
Pharmazie; 1998 Jul; 53(7):438-41. PubMed ID: 9699220
[TBL] [Abstract][Full Text] [Related]
14. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
Abaimov DA; Zimin IA; Kovalev GI
Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation by protein kinase C modulates agonist binding to striatal dopamine D2 receptors.
Rogue P; Zwiller J; Malviya AN; Vincendon G
Biochem Int; 1990 Nov; 22(3):575-82. PubMed ID: 1981673
[TBL] [Abstract][Full Text] [Related]
16. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
17. Investigation of mixed D2/5-HT1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines.
Roglić G; Dukić-Stefanović S; Andrić D; Kostić-Rajacić S; Soskić V
Pharmazie; 2001 Oct; 56(10):803-7. PubMed ID: 11683128
[TBL] [Abstract][Full Text] [Related]
18. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.
Videbaek C; Toska K; Scheideler MA; Paulson OB; Moos Knudsen G
Synapse; 2000 Dec; 38(3):338-42. PubMed ID: 11020237
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
Seeman P
Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
[TBL] [Abstract][Full Text] [Related]
20. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.
Jerning E; Malmberg A; Mohell N
J Recept Signal Transduct Res; 1995; 15(1-4):503-15. PubMed ID: 8903960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
